Results 71 to 80 of about 82,781 (316)

Comparative analysis of the tear protein profile in herpes simplex virus type 1 epithelial keratitis

open access: yesBMC Ophthalmology, 2020
Background Herpes simplex virus type 1 (HSV-1) keratitis is a major cause of corneal blindness in the world, and an in-depth understanding of its pathogenesis may help improve existing diagnosis and treatment.
Hua Yang   +5 more
doaj   +1 more source

Nanoparticle Therapeutics in Clinical Perspective: Classification, Marketed Products, and Regulatory Landscape

open access: yesSmall, EarlyView.
This review presents a detailed overview of clinically approved nanoparticle therapeutics, classifying them by type and discussing their unique advantages in drug delivery. It highlights regulatory challenges across global markets and emphasizes the need for adaptive approval pathways.
Nimeet Desai   +5 more
wiley   +1 more source

Automatic diagnosis of keratitis using object localization combined with cost-sensitive deep attention convolutional neural network

open access: yesJournal of Big Data, 2023
Keratitis is a major cause of corneal blindness worldwide. Early identification and timely treatment of keratitis can deter the disease progression, reaching a better prognosis.
Jiewei Jiang   +11 more
doaj   +1 more source

Effectiveness of the spot-on combination of moxidectin and imidacloprid (Advocate®) in the treatment of ocular thelaziosis by Thelazia callipaeda in naturally infected cats [PDF]

open access: yes, 2019
Background: The present study evaluated the therapeutic effectiveness of moxidectin 1.0% (w/v) and imidacloprid 10% (w/v) (Advocate® spot-on solution for cats, Bayer Animal Health) against natural infections with the eyeworm Thelazia callipaeda in cats ...
Capelli, G.   +8 more
core   +1 more source

Tralokinumab Treatment in Adult Atopic Dermatitis Patients: 28‐Week Evaluation of Clinical Effectiveness, Safety, Serum Proteins and Total IgE Levels

open access: yesAllergy, Volume 80, Issue 4, Page 1060-1073, April 2025.
This study evaluated 28‐week safety and effectiveness of tralokinumab treatment in patients with atopic dermatitis. All primary outcomes significantly improved during 28 weeks of tralokinumab treatment and the probability of achieving EASI ≤ 7 and NRS‐pruritis ≤ 4 was 75.8% (56.9–88.2) and 51.4% (28.0–74.2), respectively.
Coco Dekkers   +16 more
wiley   +1 more source

Acanthamoeba and Stenotrophomonas maltophilia keratitis with fungal keratitis in the contralateral eye

open access: yesClinical Ophthalmology, 2010
Thomas F Mauger, Rebecca Ann Kuennen, Reynell Harder Smith, William SawyerDepartment of Ophthalmology, The Ohio State University, Columbus, OH, USAPurpose: The purpose of this study is to describe the diagnosis, course, and outcome of a case of ...
Thomas F Mauger   +3 more
doaj  

Effect of recombinant human nerve growth factor eye drops in patients with dry eye: a phase IIa, open label, multiple-dose study [PDF]

open access: yes, 2019
Background: Dry eye disease (DED) affects more than 14% of the elderly population causing decrease of quality of life, high costs and vision impairment.
Allegretti, M.   +7 more
core   +1 more source

Incidence, risk factors, and patient characteristics in severe contact lens‐related microbial keratitis

open access: yesActa Ophthalmologica, Volume 103, Issue 3, Page 289-294, May 2025.
Abstract Purpose The aim of the present study was to determine the incidence, patient characteristics, and risk factors for severe, contact lens‐related keratitis in patients in need of hospitalization. Methods Keratitis was defined as severe when the disease required hospitalization. All patients with contact lens‐related keratitis hospitalized at our
Martin Harvey Sund   +6 more
wiley   +1 more source

Post Keratoplasty Keratitis with Pandrug Resistant Pseudomonas spp. Showing False Susceptibility to Carbapenems

open access: yesAsian Journal of Medical Sciences, 2013
Pandrug resistant Pseudomonas keratitis is an emerging cause of bacterial keratitis challenging clinicians for prompt and prudent treatment to avoid disaster of loss of eye.
Munesh K Gupta
doaj   +1 more source

Can the choice of artificial tears harm patients? A narrative review with an overview of the Nordic market

open access: yesActa Ophthalmologica, EarlyView.
Abstract Purpose To provide an overview of artificial tears marketed in the following Nordic countries: Denmark, Finland, Norway, Iceland and Sweden. Furthermore, this review aimed to highlight the different preservatives and other constituents found in artificial tears in the Nordic market, focussing on adverse effects.
K. N. Mikha   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy